Johnson & Johnson (JNJ) 10-K risk factor changes: FY2020 vs FY2019
The 2021-01-03 10-K against the 2019-12-29 one, compared heading by heading and sentence by sentence.
Item 1A42 rewritten51 added12 removed89 unchanged
All filing items1,715 rewritten945 added873 removed1,064 unchanged
Summary
counted, not written
- Item 1A lists 17 risk factor headings: 4 new, 1 reworded and 12 unchanged since FY2019. 0 headings from FY2019 no longer appear.
- Sentence by sentence, 945 added, 873 removed, 1,715 rewritten and 1,064 unchanged across 18 items that differ.
New Item 1A headings (4)
- The COVID-19 pandemic has adversely impacted certain aspects of the Company’s business and could cause disruptions or future impact to the Company’s business, results of operations and financial condition.
- Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
- Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce.
- Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
Removed Item 1A headings (0)
Every FY2019 risk factor heading is still here, word for word or reworded.
Reworded Item 1A headings (1)
- The Company faces
[removed: increasing][added: significant] regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
A heading is new when no FY2019 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
22 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2020; struck-through words were in FY2019. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. RISK FACTORS
42 rewritten, 51 added, 12 removed, 89 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Outside the U.S., numerous major markets, including the [removed: EU] [added: EU, United Kingdom] and Japan, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company’s products, or reduce the value of its intellectual property protection.
The [removed: most] [added: Company's more] significant [removed: of these] [added: legal] proceedings are described in Note [removed: 21,] [added: 19,] “Legal Proceedings” under Notes to the Consolidated Financial Statements included in Item 8 of this Report.
Some of these matters may include thousands of [removed: plaintiffs or may be determined to be class actions and] [added: plaintiffs,] may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years.
Concerns about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the [removed: FDA] [added: U.S. Food and Drug Administration] (or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage.
In connection with the [added: 2015] Organization for Economic Cooperation and Development Base Erosion and Profit Shifting (BEPS) project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries.
The Company owns or licenses a significant number of patents and other proprietary rights, [removed: determined by patent offices, courts and lawmakers in various countries,] relating to its products and manufacturing processes.
The Company cannot be certain that it will obtain adequate patent protection for new products and technologies in the [removed: U.S.] [added: United States] and other important markets or that such protections, once granted, will last as long as originally anticipated.
Competitors routinely challenge the validity or extent of the Company’s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other [removed: proceedings.][added: proceedings, such as inter partes review (IPR) proceedings before the United States Patent & Trademark Office (USPTO).]
In the U.S., manufacturers of generic versions of innovative human pharmaceutical products may challenge the validity, or claim non-infringement, of innovator products through the Abbreviated New Drug Application, or ANDA, process with the [removed: FDA.][added: FDA and related ANDA litigation.]
The [removed: inter partes review (IPR)] [added: IPR] process with the [removed: USPTO, created under the 2011 America Invents Act,] [added: USPTO] is also being used by competitors to challenge patents [removed: held by the Company’s subsidiaries.][added: asserted in litigation.]
Current legal proceedings involving the Company’s patents and other intellectual property rights are described in Note [removed: 21,] [added: 19,] “Legal Proceedings—Intellectual Property” of the Notes to the Consolidated Financial Statements included in Item 8 of this Report.
The Company’s consumer [added: health] businesses face intense competition from other branded products and retailers’ private-label brands.
New products introduced within the past five years accounted for approximately 25% of [removed: 2019] [added: 2020] sales.
Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger [removed: real world] [added: real-world] patient populations, as well as market entry of competitive products.
The Company faces [removed: increasing] [added: significant] regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
Regulatory issues regarding compliance with [added: current] Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation.
[removed: Increased scrutiny] [added: Scrutiny] of health care industry business practices [removed: in recent years] by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs.
[removed: The most significant current investigations and] litigation brought by government agencies are described in Note [removed: 21,] [added: 19,] “Legal Proceedings-Government Proceedings” under Notes to the Consolidated Financial Statements included in Item 8 of this Report.
The Company faces a variety of risks associated with conducting business [removed: internationally.][added: internationally.]
*Foreign Currency Exchange*: In fiscal [removed: 2019,] [added: 2020,] approximately [removed: 49%] [added: 48%] of the Company’s sales occurred outside of the U.S., with approximately 23% in Europe, 7% in the Western Hemisphere, excluding the U.S., and [removed: 19%] [added: 18%] in the Asia-Pacific and Africa region.
While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, [added: unhedged exposures continue to be subject to currency fluctuations.]
Also, in many countries outside the U.S., the health care providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; [removed: therefore, the Company’s interactions with these prescribers and purchasers are subject to regulation under the FCPA.]
[removed: | • |] [added: -] protective economic policies taken by governments such as trade protection measures and import/export licensing requirements; [removed: |]
[removed: | • |] [added: -] compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company’s ability to manufacture or sell its products in the relevant market; [removed: |]
[removed: | • |] [added: -] diminished protection of intellectual property and contractual rights in certain jurisdictions; [removed: |]
[removed: | • |] [added: -] potential nationalization or expropriation of the Company’s foreign assets; [removed: and |]
[removed: | • |] [added: - geopolitical events, including natural disasters,] disruptions to markets due to war, armed conflict, terrorism, [removed: social upheavals] [added: epidemics] or pandemics. [removed: |]
The Company's subsidiaries operate [removed: 97] [added: 90] manufacturing facilities as well as sourcing from hundreds of suppliers around the world.
Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, political [removed: unrest and] [added: unrest,] terrorist [removed: attacks.][added: attacks and epidemics or pandemics.]
Any failure by or loss of a [removed: third party] [added: third-party] manufacturer could result in delays and increased costs, which may adversely affect our business.
We depend on these third party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality [added: and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices.]
However, we cannot guarantee that these [removed: third party] [added: third-party] manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business.
Other risks associated with our reliance on third [removed: parties] [added: parties, including the Company’s strategic partnership with Jabil in the Medical Devices segment,] to manufacture these products [removed: include,] [added: include] reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company’s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us.
Moreover, if any of our third party manufacturers suffer any damage to facilities, lose benefits under material agreements, experience power outages, encounter financial difficulties, are unable to secure necessary raw materials from their suppliers or suffer any other reduction in efficiency, the Company may [removed: experience significant business disruption.]
In the event of any such disruption, the Company would need to seek and source other qualified [removed: third party] [added: third-party] manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.
Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are [removed: manufactured-often] [added: manufactured – often] in unregulated, unlicensed, uninspected and unsanitary [removed: sites-as] [added: sites – as] well as the lack of regulation of their contents.
An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or [removed: reputation][added: reputation.]
To meet business objectives, the Company relies on both internal [removed: information] technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data, including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal [removed: protection.][added: protection, and ensure the continuity of the Company’s supply chain.]
The extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of these [removed: IT] systems and networks, and the confidentiality, integrity, and availability of the Company’s sensitive data.
The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company’s [removed: third party] [added: third-party] providers have required capabilities and controls, to address this risk.
An investment in the Company’s common stock or debt securities involves risks and uncertainties.
The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company's control and cannot therefore be eliminated.
Risks Related to Our Business, Industry and Operations
| | | | | | | 7 | | |
experience significant business disruption.
The COVID-19 pandemic has adversely impacted certain aspects of the Company’s business and could cause disruptions or future impact to the Company’s business, results of operations and financial condition.
We are subject to risks associated with global health crises and pandemics, including the global outbreak of the novel coronavirus and its mutations (COVID-19).
The COVID-19 pandemic has adversely impacted, and is expected to continue to adversely impact, certain aspects of the Company’s business, results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products.
The spread of COVID-19 has caused the Company to modify its business practices (including instituting remote work for many of the Company's employees), and the Company may take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners.
The Company continues to monitor the situation and while we have robust business continuity plans in place across our global supply chain network to help mitigate the impact of COVID-19, these efforts may not completely prevent our business from being adversely affected and future impacts remain uncertain.
While the U.S. and other countries have begun or will begin to reopen their economies, the extent to which COVID-19 will impact the Company's future operations will depend on many factors which cannot be predicted with confidence, including the duration of the outbreak.
Any resurgence in COVID-19 infections could result in the imposition of new mandates and prolonged restrictive measures implemented in order to control the spread of the disease.
The continued global spread of COVID-19 could adversely impact the Company's operations, including, among other things, our manufacturing operations, supply chain, including third-party suppliers, sales and marketing and clinical trial operations.
Any of these factors could adversely affect the Company's business, financial results, and global economic conditions generally.
We also face uncertainties related to our efforts to develop a COVID-19 vaccine candidate, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities; risks associated with clinical trial data, including further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the JNJ-78436735 vaccine candidate and dose level for the Phase 3 (ENSEMBLE) trial; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; disruptions in the relationships between us, our third-party suppliers and external manufacturers; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis, that we may experience manufacturing delays once a manufacturing site is activated, or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated, and other challenges and risks associated with the pace of our vaccine development program; and pricing and access challenges for such products, including in the U.S.
In addition, to the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section and those incorporated by reference herein, including risks relating to the Company’s effective tax rate as a result of changes in consumption as well as changes in
| | | | | | | 8 | | |
laws relating to supply of the Company’s products.
Given that developments concerning the COVID-19 pandemic have been constantly evolving, additional impacts and risks may arise, including litigation, that are not presently known to the Company.
Risk Related to the Government Regulation and Legal Proceedings
The Company does not purchase third-party product liability insurance; however the Company utilizes a wholly-owned captive insurance company subject to certain limits.
The most significant current investigations and
| | | | | | | 9 | | |
Risks Related to Our Intellectual Property
Risks Related to Product Development, Regulatory Approval and Commercialization
| | | | | | | 10 | | |
Risk Related to Financial and Economic Market Conditions
| | | | | | | 11 | | |
therefore, the Company’s interactions with these prescribers and purchasers are subject to regulation under the FCPA.
- political or social upheavals, economic instability, repression, or human rights issues; and
Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
We currently maintain investment grade credit ratings with Moody's Investors Service and Standard & Poor's Ratings Services.
Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors.
Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts.
There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets.
Other Risks
Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce.
Our continued growth requires us to recruit and retain talented employees representing diverse backgrounds, experiences, and skill sets.
The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization.
Maintaining our brand and reputation, as well as a diverse, equitable and inclusive work environment enables us to attract top talent.
The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company's control.
Furthermore, as a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance.
| | | 6 |
In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020.
As of December 29, 2019, certain cantons where the Company operates have not yet enacted portions of the tax reform as stipulated in the Swiss Federal law.
These enactments and future possible guidance from the applicable taxing authorities may have a material impact on the Company’s operating results.
| | | 7 |
| | | 8 |
unhedged exposures continue to be subject to currency fluctuations.
| | | 9 |
and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices.
| | | 10 |
An excerpt. Shown here: 40 of 42 rewritten, 40 of 51 added and all 12 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2020 filing and the FY2019 filing.
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION
250 rewritten, 236 added, 163 removed, 158 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Johnson & Johnson and its subsidiaries (the Company) have approximately [removed: 132,200] [added: 134,500] employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field.
The Company is organized into three business segments: [removed: Consumer,] [added: Consumer Health (previously referred to as Consumer),] Pharmaceutical and Medical Devices.
The Consumer [added: Health] segment includes a broad range of products used in the baby care, oral care, [removed: beauty,] [added: skin health/beauty,] over-the-counter pharmaceutical, women’s health and wound care markets.
These products are marketed to the general public and sold [removed: both] [added: online (eCommerce) and] to retail outlets and distributors throughout the world.
This Committee oversees and coordinates the activities of the [removed: Consumer,] [added: Consumer Health,] Pharmaceutical and Medical Devices business segments.
New products introduced within the past five years accounted for approximately 25% of [removed: 2019] [added: 2020] sales.
In [removed: 2019, $11.4] [added: 2020, $12.2] billion was invested in research and development and [removed: $5.8] [added: $7.3] billion spent on acquisitions, reflecting management’s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly change the trajectory of health for humanity.
A critical driver of the Company’s success is the [removed: 132,200] [added: 134,500] diverse employees worldwide.
Leveraging the extensive resources across the [removed: enterprise,] [added: enterprise] enables the Company to innovate and execute with excellence.
[removed:   ][added: ]
For discussion on results of operations and financial condition pertaining to the fiscal years [removed: 2018] [added: 2019] and [removed: 2017] [added: 2018] see the Company’s Annual Report on Form 10-K for the fiscal year ended December [removed: 30, 2018,] [added: 29, 2019,] Item 7.
In [removed: 2019,] [added: 2020,] worldwide sales increased 0.6% to [removed: $82.1] [added: $82.6] billion as compared to an increase of [removed: 6.7%] [added: 0.6%] in [removed: 2018.][added: 2019.]
| Sales increase/(decrease) due to: | | [added: | | | | 2020 | | | | | |] 2019 | | | [removed: 2018] | | [added: | | | |]
| Volume | | [removed: 3.7] | [added: | | | 3.5 | |] % | | [removed: 8.5] | [added: | 3.7 | |] % | [added: | | | | | |]
| Price | | [removed: (0.9] | [removed: )] | | [removed: (2.2] | [removed: )] [added: (2.3)] | [added: | | | | | (0.9) | | | | | | | | |]
| Currency | | [removed: (2.2] | [removed: )] | | [removed: 0.4] | [added: (0.6)] | [added: | | | | | (2.2) | | | | | | | | |]
| Total | | [added: | | | |] 0.6 | [added: |] % | | [removed: 6.7] | [added: | 0.6 | |] % | [added: | | | | | |]
The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of [removed: 1.7%] [added: 0.3%] in [removed: 2019] [added: 2020] and a [removed: positive] [added: negative] impact of [removed: 0.8%] [added: 1.7%] in [removed: 2018.][added: 2019.]
Sales by U.S. companies were [removed: $42.1] [added: $43.1] billion in [removed: 2019] [added: 2020] and [removed: $41.9] [added: $42.1] billion in [removed: 2018.][added: 2019.]
This represents increases of [removed: 0.5%] [added: 2.5%] in [removed: 2019] [added: 2020] and [removed: 5.1%] [added: 0.5%] in [removed: 2018.][added: 2019.]
Sales by international companies were [removed: $40.0] [added: $39.5] billion in [removed: 2019] [added: 2020] and [removed: $39.7] [added: $40.0] billion in [removed: 2018.][added: 2019.]
This represents [added: a decrease of 1.3% in 2020 and] an increase of 0.7% in [removed: 2019 and 8.5% in 2018.][added: 2019.]
The five-year compound annual growth rates for worldwide, U.S. and international sales were [removed: 2.0%,] [added: 3.3%,] 3.9% and [removed: 0.2%,] [added: 2.8%,] respectively.
The ten-year compound annual growth rates for worldwide, U.S. and international sales were [removed: 2.9%, 3.1%] [added: 3.0%, 3.9%] and [removed: 2.6%,] [added: 2.1%,] respectively.
[removed: In 2019, sales] [added: Sales] by companies in [removed: Europe] [added: the Western Hemisphere (excluding the U.S.)] experienced a sales decline of [removed: 1.5%] [added: 10.2%] as compared to the prior year, which included operational growth of [removed: 3.8%] [added: 0.4%] offset by a negative currency impact of [removed: 5.3%.][added: 10.6%.]
[removed: Sales] [added: In 2020, sales] by companies in [removed: the Western Hemisphere (excluding the U.S.) experienced a sales decline] [added: Europe achieved growth] of 2.8% as compared to the prior year, which included operational growth of [removed: 5.7% offset by] [added: 2.0% and] a [removed: negative] [added: positive] currency impact of [removed: 8.5%.][added: 0.8%.]
Sales by companies in the Asia-Pacific, Africa region [removed: achieved growth] [added: experienced a sales decline] of [removed: 4.9%] [added: 2.7%] as compared to the prior year, including [added: an] operational [removed: growth] [added: decline] of [removed: 6.9%] [added: 3.1%] partially offset by a [removed: negative] [added: positive] currency impact of [removed: 2.0%.][added: 0.4%.]
In 2019, the Company [removed: utilized] [added: had] three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues.
In [removed: 2018,] [added: 2020,] the Company [removed: had] [added: utilized] three wholesalers distributing products for all three segments that represented approximately [removed: 14.0%, 11.0%] [added: 16.0%, 12.0%] and [removed: 11.0%] [added: 12.0%] of the total consolidated revenues.
[removed: ][added: ]
Consumer [added: Health] Segment
Consumer [added: Health] segment sales in [removed: 2019] [added: 2020] were [removed: $13.9] [added: $14.1] billion, an increase of [removed: 0.3%] [added: 1.1%] from [removed: 2018,] [added: 2019,] which included 3.0% operational growth and a negative currency impact of [removed: 2.7%.][added: 1.9%.]
U.S. Consumer [added: Health] segment sales were [removed: $5.8] [added: $6.4] billion, an increase of [removed: 1.4%.][added: 9.0%.]
International sales were [removed: $8.1] [added: $7.7] billion, a decrease of [removed: 0.4%,] [added: 4.6%,] which included [removed: 4.2%] [added: an] operational [removed: growth] [added: decline of 1.3%] and a negative currency impact of [removed: 4.6%.][added: 3.3%.]
In [removed: 2019,] [added: 2020,] acquisitions and divestitures had a net [removed: positive] [added: negative] impact of [removed: 1.6%] [added: 0.1%] on the operational sales growth of the worldwide Consumer [added: Health] segment.
Major Consumer [added: Health] Franchise [removed: Sales:][added: Sales*:]
| | | | | | | | | | [added: | | | | | | | | |] % Change | | [added: |]
| (Dollars in Millions) | | [removed: 2019] | | | | [removed: 2018] [added: 2020] | | | [removed: ’19] [added: | | | 2019 | | | | | | ’20] vs. [removed: ’18] [added: ’19] | | [added: |]
| Baby Care | | [added: | | | | 1,517 | | | | | |] 1,675 | | | | [removed: 1,858] | | [added: (9.4)] | [removed: (9.9] | [removed: )] |
| Oral Care | | [added: | | | | 1,641 | | | | | |] 1,528 | | | | [removed: 1,555] | | [added: 7.4] | [removed: (1.7] | [removed: )] |
  
| | | | | | | 19 | | |
The 2020 results benefited from the inclusion of a 53rd week.
The Company estimated that the fiscal year 2020 sales growth rate was enhanced by approximately 1.0%.
While the additional week added a few days to sales, it also added a full week's worth of operating costs; therefore, the net earnings impact was negligible.
Note: values may have been rounded
| | | | | | | 20 | | |
| OTC | | | | | | $ | 4,824 | | | | | 4,444 | | | | | | 8.5 | | % |
| Skin Health/Beauty | | | | | | 4,450 | | | | | | 4,593 | | | | | | (3.1) | | |
| * Previously referred to as Consumer Previously referred to as Beauty | | | | | | | | | | | | | | | | | | | | |
Growth was primarily attributable to sales from TYLENOL® driven by COVID-19 stocking demand, ZYRTEC® due to competitor product out of stock and PEPCID® due to competitive product withdrawal both in the U.S., and increased consumption in anti-smoking aids.
International sales were negatively impacted by COVID-19 and low incidence of cough and flu.
The Skin Health/Beauty franchise sales were $4.5 billion in 2020, a decrease of 3.1% as compared to the prior year.
The decline was primarily due to negative COVID-19 related impacts and SKU rationalization partially offset by growth in eCommerce and new product innovation.
The Oral Care franchise sales of $1.6 billion increased 7.4% as compared to the prior year primarily attributable to sales of LISTERINE® mouthwash due to U.S. eCommerce and club channel growth, increased stocking demand related to COVID-19 and new product launches in Asia Pacific.
The decline was primarily due to COVID-19 related impacts, SKU rationalization and the Baby Center divestiture in the U.S. partially offset by strength in AVEENO® baby.
The decline was primarily driven by COVID-19 impacts.
Growth was due to strong performance of NEOSPORIN® and BAND-AID® Brand Adhesive Bandages and COVID-19 related demand in the Asia Pacific region.
| | | | | | | 21 | | |
| REMICADE® | | | | | | 3,747 | | | | | | 4,380 | | | | | | | | | | | | (14.4) | | | | | | | | |
| STELARA® | | | | | | 7,707 | | | | | | 6,361 | | | | | | | | | | | | 21.1 | | | | | | | | |
| TREMFYA® | | | | | | 1,347 | | | | | | 1,012 | | | | | | | | | | | | 33.2 | | | | | | | | |
| DARZALEX® | | | | | | 4,190 | | | | | | 2,998 | | | | | | | | | | | | 39.8 | | | | | | | | |
| ERLEADA®(1) | | | | | | 760 | | | | | | 332 | | | | | | | | | | | | | | | | | | | | |
| IMBRUVICA® | | | | | | 4,128 | | | | | | 3,411 | | | | | | | | | | | | 21.0 | | | | | | | | |
| VELCADE® | | | | | | 408 | | | | | | 751 | | | | | | | | | | | | (45.7) | | | | | | | | |
| Other Oncology | | | | | | 413 | | | | | | 407 | | | | | | | | | | | | 1.7 | | | | | | | | |
| OPSUMIT® | | | | | | 1,639 | | | | | | 1,327 | | | | | | | | | | | | 23.5 | | | | | | | | |
| UPTRAVI® | | | | | | 1,093 | | | | | | 819 | | | | | | | | | | | | 33.5 | | | | | | | | |
| Other Pulmonary Hypertension (2) | | | | | | 416 | | | | | | 476 | | | | | | | | | | | | (12.8) | | | | | | | | |
| XARELTO® | | | | | | 2,345 | | | | | | 2,313 | | | | | | | | | | | | 1.4 | | | | | | | | |
| Other | | | | | | 1,186 | | | | | | 1,353 | | | | | | | | | | | | (12.4) | | | | | | | | |
(1) Previously included in Other Oncology
(2) Inclusive of TRACLEER® which was previously disclosed separately
| | | | | | | 22 | | |
Immunology products sales were $15.1 billion in 2020, representing an increase of 7.9% as compared to the prior year driven by strong uptake of STELARA® (ustekinumab) in Crohn's disease and Ulcerative Colitis and strength in TREMFYA® (guselkumab) in Psoriasis.
Infectious disease products sales were $3.6 billion in 2020, representing an increase of 4.7% as compared to the prior year primarily due to strong sales of SYMTUZA® and JULUCA®.
The growth was partially offset by migration from RISPERDAL CONSTA® (risperidone) and declines in CONCERTA® (methylphenidate) due to competitive entrants.
Additionally, sales of TRACLEER® (bosentan) were negatively impacted by generics and migration to OPSUMIT®.
Sales growth of INVOKANA®/INVOKAMET® (canagliflozin) were due to market growth and favorable channel mix dynamics in the U.S. and strength in the European region partially offset by U.S. share declines due to competitive pressures.
| | | 17 |
| | | 18 |
| Beauty | | $ | 4,593 | | | 4,382 | | | 4.8 | % |
| OTC | | 4,444 | | | | 4,334 | | | 2.5 | |
Growth was primarily driven by incremental sales from the acquisition of Ci:z Holdings Co., Ltd., (DR.CI:LABO) in Japan as well as market growth and share gains of NEUTROGENA® and AVEENO® products.
Growth was partially offset by the divestitures of RoC® and NIZORAL® in the fiscal year 2018.
The Over-the-Counter (OTC) franchise sales of $4.4 billion increased 2.5% as compared to the prior year.
Growth was primarily driven by incremental sales from the acquisition of ZARBEES®.
Additional contributors to the growth were TYLENOL®, Children's MOTRIN®, digestive health products and anti-smoking aids.
The Baby Care franchise sales were $1.7 billion in 2019, a decrease of 9.9% compared to the prior year, primarily due to JOHNSON’s® competitive pressures coupled with comparisons to prior year relaunch activities and the Baby Center divestiture.
Growth in LISTERINE® Mouthwash and Ready Tabs outside the U.S. was offset by share declines and retailer destocking in the U.S. and the negative impact of currency.
The decline was primarily driven by the negative impact of currency and weakness in liners partially offset by strength in napkins in Asia Pacific and Latin America.
| | | 19 |
| REMICADE® | | 4,380 | | | | 5,326 | | | (17.8 | ) |
| STELARA® | | 6,361 | | | | 5,156 | | | 23.4 | |
| TREMFYA® | | 1,012 | | | | 544 | | | 85.9 | |
| DARZALEX® | | 2,998 | | | | 2,025 | | | 48.0 | |
| IMBRUVICA® | | 3,411 | | | | 2,615 | | | 30.4 | |
| VELCADE® | | 751 | | | | 1,116 | | | (32.7 | ) |
| Other Oncology | | 739 | | | | 590 | | | 25.0 | |
| OPSUMIT® | | 1,327 | | | | 1,215 | | | 9.2 | |
| TRACLEER® /bosentan | | 341 | | | | 546 | | | (37.5 | ) |
| UPTRAVI® | | 819 | | | | 663 | | | 23.5 | |
| Other Pulmonary Hypertension | | 135 | | | | 149 | | | (9.4 | ) |
| XARELTO® | | 2,313 | | | | 2,477 | | | (6.6 | ) |
| Other | | 1,353 | | | | 1,470 | | | (8.0 | ) |
| | | 20 |
Growth was driven by strong uptake of STELARA® (ustekinumab) in Crohn's disease, and TREMFYA® (guselkumab) in Psoriasis, expanded indications of SIMPONI®/SIMPONI ARIA® (golimumab), and the U.S. immunology market growth.
Oncology products achieved sales of $10.7 billion in 2019, representing an increase of 8.6% as compared to the prior year.
Additionally, sales from the launch of ERLEADA™ (apalutamide) contributed to the growth.
Pulmonary Hypertension products achieved sales of $2.6 billion, representing an increase of 1.9% as compared to the prior year.
| | | 21 |
| BALVERSA™ (erdafitinib) | Treatment of locally advanced or metastatic urothelial cancer | Ÿ | | | |
| | Split-dosing regimen | Ÿ | | | |
| | Combination therapy for transplant ineligible Multiple Myeloma patients | | Ÿ | Ÿ | |
| | Subcutaneous Formulation in Multiple Myeloma | | | Ÿ | Ÿ |
| | Treatment of Metastatic Hormone-Sensitive Prostate Cancer | | | | Ÿ |
| | Treatment for Chronic Lymphocytic Leukemia in combination with obinutuzumab | Ÿ | | | |
| SPRAVATO® (esketamine) | Treatment-resistant depression | Ÿ | Ÿ | | |
| STELARA® (ustekinumab) | Extended Use for the Treatment of Moderately to Severely Active Ulcerative Colitis | Ÿ | Ÿ | | |
An excerpt. Shown here: 40 of 250 rewritten, 40 of 236 added and 40 of 163 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION in the FY2020 filing and the FY2019 filing.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
0 rewritten, 1 added, 1 removed, 2 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| | | | | | | 37 | | |
| | | 33 |
Item 1. BUSINESS
25 rewritten, 83 added, 16 removed, 76 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Johnson & Johnson and its subsidiaries (the Company) have approximately [removed: 132,200] [added: 134,500] employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field.
This Committee oversees and coordinates the activities of the Company's three business segments: [removed: Consumer,] [added: Consumer Health (previously referred to as Consumer),] Pharmaceutical and Medical Devices.
The Company is organized into three business segments: [removed: Consumer,] [added: Consumer Health,] Pharmaceutical and Medical Devices.
Management’s Discussion and Analysis of Results of Operations and Financial Condition” of this Report; and Note [removed: 18] [added: 17] “Segments of Business and Geographic Areas” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
[removed: Consumer][added: Consumer Health]
The Consumer [added: Health] segment includes a broad range of products focused on personal healthcare used in the [removed: beauty,] [added: skin health/beauty,] over-the-counter [removed: pharmaceutical,] [added: medicines,] baby care, oral care, women’s health and wound care markets.
Major brands in [removed: Beauty] [added: skin health/beauty] include the AVEENO®; CLEAN & CLEAR®; DR. CI:LABO®; NEUTROGENA® and OGX® product lines.
Over-the-counter [added: (OTC)] medicines include the broad family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; BENADRYL® and ZYRTEC® allergy products; MOTRIN® IB ibuprofen products; NICORETTE® smoking cessation products outside the U.S.; ZARBEE’S NATURALS® and the PEPCID® line of acid reflux products.
These products are marketed to the general public and sold online [added: (eCommerce)] and to retail outlets and distributors throughout the world.
maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA® (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer; IMBRUVICA® (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers, chronic graft versus host disease and Waldenström's Macroglobulinemia; DARZALEX® (daratumumab), a treatment for relapsed/refractory multiple myeloma; [added: ERLEADA® (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer;] VELCADE® (bortezomib), a treatment for multiple myeloma mantle cell lymphoma; PROCRIT®/EPREX® (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO® (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET®/VOKANAMET® (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET® XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT® (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI® (selexipag), the only approved oral, selective IP receptor agonist targeting a prostacyclin pathway in PAH.
The Medical Devices segment includes a broad range of products used in the [removed: orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular)] [added: Interventional Solutions, Orthopaedics, Surgery,] and [removed: eye health] [added: Vision] fields.
These products are distributed to wholesalers, hospitals and retailers, and used [removed: principally] [added: predominantly] in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
Johnson & Johnson and its subsidiaries (the Company) have approximately [removed: 132,200] [added: 134,500] employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field.
The products made and sold in the international business include many of those described above under “– Segments of Business – [removed: Consumer,”] [added: Consumer Health,”] “– Pharmaceutical” and “– Medical Devices.” However, the principal markets, products and methods of distribution in the international business vary with the country and the culture.
Significant legal proceedings and claims involving the Company's patent and other intellectual property are described in Note [removed: 21,] [added: 19,] “Legal Proceedings—Intellectual Property” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Sales of the Company’s largest product, STELARA® (ustekinumab), accounted for approximately [removed: 7.8%] [added: 9.3%] of the Company's total revenues for fiscal [removed: 2019.][added: 2020.]
[removed: This set of patents is owned by] Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson & [removed: Johnson.][added: Johnson, owns patents specifically related to STELARA®.]
[removed: We are] [added: The Company is] subject to costly and complex U.S. and foreign laws and governmental regulations and any adverse regulatory action may materially adversely affect [removed: our] [added: the Company's] financial condition and business operations.
The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the [added: U.S.] FDA) continues to result in increases in the amounts of testing and documentation required for [added: U.S.] FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.
The [added: U.S.] FDA and regulatory agencies around the globe are also increasing their enforcement activities.
There is increased focus on interactions [removed: between healthcare companies] and [removed: health care providers and various transparency laws and regulations require disclosures of] financial relationships between [added: healthcare] companies and health care providers.
U.S. government agencies continue efforts to [removed: repeal and modify] [added: repeal, modify, or invalidate] provisions of the Patient Protection and Affordable Care Act (the ACA) which passed in 2010.
For example, federal legislation repealed the ACA’s individual mandate tax penalty as well as the tax on generous employer-sponsored healthcare plans; [removed: CMS] [added: the Center for Medicare & Medicaid Services (CMS)] began permitting states to impose work requirements on persons covered by Medicaid expansion plans; certain federal subsidies to insurers have ended; and certain short-term insurance plans not offering the full array of ACA benefits have been allowed to extend in duration.
Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements, and may be faced with unexpected changes such as those resulting from [added: the COVID-19 pandemic and] Brexit, that may affect sourcing, supply and pricing of materials used in the Company's products.
In addition, the [added: Amended and] Restated Certificate of Incorporation, By-Laws, the written charters of the Audit Committee, the Compensation & Benefits Committee, the Nominating & Corporate Governance Committee, the Regulatory Compliance Committee and the Science, Technology & Sustainability Committee of the Board of Directors and the Company’s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials, are available at *www.investor.jnj.com/gov.cfm* on the Company's website and will be provided without charge to any shareholder submitting a written request, as [added: provided above.]
| | | | | | | 1 | | |
Medical Devices in Interventional Solutions include Electrophysiology products (Biosense Webster) to treat cardiovascular diseases, Neurovascular care (Cerenovus) that treats hemorrhagic and ischemic stroke; the Orthopaedics portfolio (DePuy Synthes) is comprised of products in support of Hips, Knees, Trauma, and Spine, Sports & Other; the Surgery portfolios (Ethicon) include advanced and general surgery offerings, solutions that focus on Breast Aesthetics (Mentor) and Ear, Nose and Throat (Acclarent) procedures; and Johnson & Johnson Vision products such as ACUVUE® Brand disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery.
| | | | | | | 2 | | |
The latest expiring United States patent expires in 2023.
The latest expiring European patent expires in 2024.
Sales of the Company’s second largest product, DARZALEX® (daratumumab) and DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), accounted for approximately 5.1% of the Company's total revenues for fiscal 2020.
Accordingly, the patents related to this product are believed to be material to the Company.
Genmab A/S owns patents related to DARZALEX®, and Janssen Biotech, Inc. has an exclusive license to those patents.
The latest expiring licensed United States patent expires in 2029.
The latest expiring licensed European patent expires in 2031.
Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO™.
Sales of the Company’s third largest product, IMBRUVICA® (ibrutinib), accounted for approximately 5.0% of the Company's total revenues for fiscal 2020.
Accordingly, patents related to this product are believed to be material to the Company.
Pharmacyclics LLC (an AbbVie company) owns the patents related to IMBRUVICA®, and Janssen Biotech, Inc. has an exclusive license to those patents.
The Pharmacyclics patents and their expiration dates are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
Pharmacyclics LLC and Janssen Biotech, Inc. have entered into confidential settlement agreements with certain generic companies granting licenses to market their generic ibrutinib products in the United States before the expiration of certain patents.
| | | | | | | 3 | | |
Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry.
Various transparency laws and regulations require disclosures of payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners.
Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official.
The ACA has also been subject to judicial challenge.
In November 2020, the U.S. Supreme Court heard argument in *Texas v.
Azar*, which challenges the constitutionality of the ACA.
Pending resolution of the litigation, all of the ACA but the individual mandate to buy health insurance remains in effect.
There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing in the Medicare and Medicaid programs.
The global regulatory landscape is also subject to change as the COVID-19 pandemic continues to affect the U.S. and global economies.
The U.S. FDA and other health authorities have shifted resources and priorities to meet the many challenges presented by the pandemic.
Pandemic-related disruptions could negatively impact the processing of regulatory submissions and slow agency review times necessary for the approval or clearance of new drugs and devices.
The duration and severity of the COVID-19 pandemic is unpredictable and difficult to assess.
| | | | | | | 4 | | |
Employees and Human Capital Management
As of January 3, 2021 and December 29, 2019, the number of employees were approximately:
| | | | 2020 | | | 2019 | | |
| Employees1 | | | 136,400 | | | 133,200 | | |
| Full-time equivalent (FTE) positions2 | | | 134,500 | | | 132,200 | | |
1“Employee” is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees.
Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded.
Contingent workers, contractors and subcontractors are also excluded.
2 FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.

| | | 1 |
They include orthopaedic products; general surgery, biosurgical, endomechanical and energy products; electrophysiology products to treat cardiovascular disease; and vision products such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery.
| | | 2 |
There is one set of granted patents related specifically to STELARA®.
These patents are in force in the U.S. and many countries outside the U.S. In the U.S., the latest projected expiration date for patents in this set is 2023 due to patent term extension and adjustment.
In most of Europe, the latest projected expiration date for patents in this set is 2024 due to a Supplementary Protection Certificate (patent term extension).
In most other countries, the latest projected expiration date is 2021.
In addition to competing in the immunology market with STELARA®, the Company is currently marketing SIMPONI® (golimumab) and SIMPONI ARIA® (golimumab), next generation immunology products.
Patents related to these products are in force and the latest projected U.S. expiration date is 2024 due to patent term extension and adjustment.
The Company also markets REMICADE® (infliximab) in the immunology market which is the Company’s 2nd largest product.
Patents on this product have expired and the Food and Drug Administration approved the first infliximab biosimilar for sale in the U.S. in 2016, and a number of such products have been launched since then.
For a more extensive description of legal matters regarding the patents related to REMICADE®, see Note 21 “Legal Proceedings - Intellectual Property - Pharmaceutical - REMICADE® Related Cases” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
| | | 3 |
| | | 4 |
provided above.
| | | 5 |
An excerpt. Shown here: all 25 rewritten, 40 of 83 added and all 16 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2020 filing and the FY2019 filing.
Item 3. LEGAL PROCEEDINGS
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
The information called for by this item is incorporated herein by reference to the information set forth in Note [removed: 21] [added: 19] “Legal Proceedings” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Cover and table of contents
76 rewritten, 24 added, 18 removed, 42 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
[removed: FORM 10-K][added: FORM 10-K]
| ☑ | [added: | |] ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 | [added: | |]
For the fiscal year [removed: ended December 29, 2019][added: ended January 3, 2021]
| ☐ | [added: | |] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of [removed: 1934 for] [added: 1934 for] the transition period from to | [added: | |]
Commission file [removed: number 1-3215][added: number 1-3215]
| New Jersey | | [added: | | | |] 22-1024240 | [added: | |]
| (State of incorporation) | | [added: | | | |] (I.R.S. Employer Identification No.) | [added: | |]
| One Johnson & Johnson [removed: Plaza New] [added: Plaza New] Brunswick, New Jersey | | [added: | | | |] 08933 | [added: | |]
| (Address of principal executive offices) | | [added: | | | |] (Zip Code) | [added: | |]
Registrant’s telephone number, including area code: [removed: (732) 524-0400][added: (732) 524-0400]
| Title of each class | [added: | |] Trading Symbol | [added: | |] Name of each exchange on which registered | [added: | |]
| Common Stock, Par Value $1.00 | [added: | |] JNJ | [added: | |] New York Stock Exchange | [added: | |]
| 0.250% Notes Due January 2022 | [removed: JNJ] | [added: | JNJ22 | | |] New York Stock Exchange | [added: | |]
| 0.650% Notes Due May 2024 | [removed: JNJ] | [added: | JNJ24C | | |] New York Stock Exchange | [added: | |]
| 5.50% Notes Due November 2024 | [removed: JNJ] | [added: | JNJ24BP | | |] New York Stock Exchange | [added: | |]
| 1.150% Notes Due November 2028 | [removed: JNJ] | [added: | JNJ28 | | |] New York Stock Exchange | [added: | |]
| 1.650% Notes Due May 2035 | [removed: JNJ] | [added: | JNJ35 | | |] New York Stock Exchange | [added: | |]
| | [added: | |] Large accelerated filer | [added: | |] ☑ | [added: | |] Accelerated filer | [added: | |] ☐ | [added: | |]
| | [added: | |] Non-accelerated filer | [added: | |] ☐ | [added: | |] Smaller reporting company | [added: | |] ☐ | [added: | |]
| | [added: | |] Emerging growth company | [added: | |] ☐ | | | [added: | | | | | |]
The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately [removed: $368] [added: $363] billion.
On February [removed: 10, 2020,] [added: 16, 2021,] there were [removed: 2,634,721,257] [added: 2,628,679,824] shares of Common Stock outstanding.
| Parts I and III: | [added: | |] Portions of registrant’s proxy statement for its [removed: 2019] [added: 2021] annual meeting of shareholders filed within 120 days after the close of the registrant’s fiscal year (the "Proxy Statement"), are incorporated by reference to this report on Form 10-K (this "Report"). | [added: | |]
| Item | | [added: | | | |] Page | [added: | |]
| | [added: | |] [Segments of [removed: Business](#s2503BE513D9351829820050D3CEA7DB7)] [added: Business](#i26b7b3066a4848f5be790a5478bde067_22)] | [removed: [1](#s2503BE513D9351829820050D3CEA7DB7)] | [added: | [1](#i26b7b3066a4848f5be790a5478bde067_22) | | |]
| | [added: | |] [Geographic [removed: Areas](#sFC67AC5291A0596F8F62A81D79CF2BDF)] [added: Areas](#i26b7b3066a4848f5be790a5478bde067_25)] | [removed: [2](#sFC67AC5291A0596F8F62A81D79CF2BDF)] | [added: | [2](#i26b7b3066a4848f5be790a5478bde067_25) | | |]
| | [added: | |] [Raw [removed: Materials](#s2BC67DB7212F539D830199E46B6156A8)] [added: Materials](#i26b7b3066a4848f5be790a5478bde067_28)] | [removed: [2](#s2BC67DB7212F539D830199E46B6156A8)] | [added: | [2](#i26b7b3066a4848f5be790a5478bde067_28) | | |]
| | [added: | |] [Available [removed: Information](#s86726D01142A55EFA604D689D7DCAE71)] [added: Information](#i26b7b3066a4848f5be790a5478bde067_49)] | [removed: [4](#s86726D01142A55EFA604D689D7DCAE71)] | [added: | [6](#i26b7b3066a4848f5be790a5478bde067_49) | | |]
| 1A. | [added: | |] [Risk [removed: Factors](#s9765DD874C545E69ADE64496D65FB833)] [added: Factors](#i26b7b3066a4848f5be790a5478bde067_52)] | [removed: [6](#s9765DD874C545E69ADE64496D65FB833)] | [added: | [7](#i26b7b3066a4848f5be790a5478bde067_52) | | |]
| 1B. | [added: | |] [Unresolved Staff [removed: Comments](#sAA29E2408B1A53378036435F14B0F743)] [added: Comments](#i26b7b3066a4848f5be790a5478bde067_55)] | [removed: [11](#sAA29E2408B1A53378036435F14B0F743)] | [added: | [13](#i26b7b3066a4848f5be790a5478bde067_55) | | |]
| 3 | [added: | |] [Legal [removed: Proceedings](#s05EB361736ED52C988E5862CFCA9C3D3)] [added: Proceedings](#i26b7b3066a4848f5be790a5478bde067_61)] | [removed: [12](#s05EB361736ED52C988E5862CFCA9C3D3)] | [added: | [15](#i26b7b3066a4848f5be790a5478bde067_61) | | |]
| 4 | [added: | |] [Mine Safety [removed: Disclosures](#sC06897F4BC0D584B9AB02FB1A1E6E169)] [added: Disclosures](#i26b7b3066a4848f5be790a5478bde067_64)] | [removed: [12](#sC06897F4BC0D584B9AB02FB1A1E6E169)] | [added: | [15](#i26b7b3066a4848f5be790a5478bde067_64) | | |]
| | [added: | |] [Executive Officers of the [removed: Registrant](#s6897C85A9E6F5C888DCCCCA489C73862)] [added: Registrant](#i26b7b3066a4848f5be790a5478bde067_67)] | [removed: [12](#s6897C85A9E6F5C888DCCCCA489C73862)] | [added: | [15](#i26b7b3066a4848f5be790a5478bde067_67) | | |]
| 5 | [added: | |] [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#s90037FBA512250A3AD025478758526E8)] [added: Securities](#i26b7b3066a4848f5be790a5478bde067_73)] | [removed: [15](#s90037FBA512250A3AD025478758526E8)] | [added: | [18](#i26b7b3066a4848f5be790a5478bde067_73) | | |]
| 7 | [added: | |] [Management’s Discussion and Analysis of Results of Operations and Financial [removed: Condition](#sD9B7A4574DC85BDC8499D386C0601F5B)] [added: Condition](#i26b7b3066a4848f5be790a5478bde067_79)] | [removed: [17](#sD9B7A4574DC85BDC8499D386C0601F5B)] | [added: | [19](#i26b7b3066a4848f5be790a5478bde067_79) | | |]
| 7A. | [added: | |] [Quantitative and Qualitative Disclosures About Market [removed: Risk](#s1D055E159C1C57B18820BAD098D45729)] [added: Risk](#i26b7b3066a4848f5be790a5478bde067_100)] | [removed: [33](#s1D055E159C1C57B18820BAD098D45729)] | [added: | [37](#i26b7b3066a4848f5be790a5478bde067_100) | | |]
| 8 | [added: | |] [Financial Statements and Supplementary [removed: Data](#sA832375D9663578AA360813C4DA1E0AE)] [added: Data](#i26b7b3066a4848f5be790a5478bde067_103)] | [removed: [34](#sA832375D9663578AA360813C4DA1E0AE)] | [added: | [38](#i26b7b3066a4848f5be790a5478bde067_103) | | |]
| 9 | [added: | |] [Changes in and Disagreements With Accountants on Accounting and Financial [removed: Disclosure](#s0476F455306F575692A0F79BD6ED0953)] [added: Disclosure](#i26b7b3066a4848f5be790a5478bde067_235)] | [removed: [109](#s0476F455306F575692A0F79BD6ED0953)] | [added: | [106](#i26b7b3066a4848f5be790a5478bde067_235) | | |]
| 9A. | [added: | |] [Controls and [removed: Procedures](#sB53FB604C55D593D95CF7240EF089AEA)] [added: Procedures](#i26b7b3066a4848f5be790a5478bde067_238)] | [removed: [109](#sB53FB604C55D593D95CF7240EF089AEA)] | [added: | [106](#i26b7b3066a4848f5be790a5478bde067_238) | | |]
| [removed: [PART III](#s63CA4A15FD0D5D51AF525E3B8AC7AB4F)] [added: [PART III](#i26b7b3066a4848f5be790a5478bde067_244)] | | | [added: | | | | | |]
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Yes ☑ No o
| [PART I](#i26b7b3066a4848f5be790a5478bde067_13) | | | | | | | | |
| 1 | | | [Business](#i26b7b3066a4848f5be790a5478bde067_16) | | | [1](#i26b7b3066a4848f5be790a5478bde067_16) | | |
| | | | [General](#i26b7b3066a4848f5be790a5478bde067_19) | | | [1](#i26b7b3066a4848f5be790a5478bde067_19) | | |
| | | | [Patents](#i26b7b3066a4848f5be790a5478bde067_31) | | | [2](#i26b7b3066a4848f5be790a5478bde067_31) | | |
| | | | [Trademarks](#i26b7b3066a4848f5be790a5478bde067_34) | | | [3](#i26b7b3066a4848f5be790a5478bde067_37) | | |
| | | | [Seasonality](#i26b7b3066a4848f5be790a5478bde067_37) | | | [3](#i26b7b3066a4848f5be790a5478bde067_37) | | |
| | | | [Competition](#i26b7b3066a4848f5be790a5478bde067_40) | | | [3](#i26b7b3066a4848f5be790a5478bde067_40) | | |
| | | | [Environment](#i26b7b3066a4848f5be790a5478bde067_43) | | | [3](#i26b7b3066a4848f5be790a5478bde067_43) | | |
| | | | [Regulation](#i26b7b3066a4848f5be790a5478bde067_46) | | | [3](#i26b7b3066a4848f5be790a5478bde067_46) | | |
| | | | [Employees and Human Capital Management](#i26b7b3066a4848f5be790a5478bde067_2653) | | | [5](#i26b7b3066a4848f5be790a5478bde067_2653) | | |
| 2 | | | [Properties](#i26b7b3066a4848f5be790a5478bde067_58) | | | [14](#i26b7b3066a4848f5be790a5478bde067_58) | | |
| [PART II](#i26b7b3066a4848f5be790a5478bde067_70) | | | | | | | | |
| 6 | | | [(](#i26b7b3066a4848f5be790a5478bde067_2723)[Reserved](#i26b7b3066a4848f5be790a5478bde067_2723)[)](#i26b7b3066a4848f5be790a5478bde067_2723) | | | [18](#i26b7b3066a4848f5be790a5478bde067_2723) | | |
| 9B. | | | [Other Information](#i26b7b3066a4848f5be790a5478bde067_241) | | | [106](#i26b7b3066a4848f5be790a5478bde067_241) | | |
| 11 | | | [Executive Compensation](#i26b7b3066a4848f5be790a5478bde067_250) | | | [107](#i26b7b3066a4848f5be790a5478bde067_250) | | |
| [PART IV](#i26b7b3066a4848f5be790a5478bde067_262) | | | | | | | | |
| 16 | | | [Form 10-K Summary](#i26b7b3066a4848f5be790a5478bde067_268) | | | [108](#i26b7b3066a4848f5be790a5478bde067_268) | | |
| | | | [Signatures](#i26b7b3066a4848f5be790a5478bde067_271) | | | [109](#i26b7b3066a4848f5be790a5478bde067_271) | | |
| | | | [Exhibit Index](#i26b7b3066a4848f5be790a5478bde067_274) | | | [111](#i26b7b3066a4848f5be790a5478bde067_274) | | |
- The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates.
- The impact of global public health crises and pandemics, including the outbreak of the novel coronavirus (COVID-19) pandemic;
Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.
| [PART I](#s776028D6AF8152E5B38CF6E90FB709B5) | | |
| 1 | [Business](#s3BA045E93A5956B2B2318FCD5124A8F2) | [1](#s3BA045E93A5956B2B2318FCD5124A8F2) |
| | [General](#s346FF33A0C2C5F81A3458BE83AC5EAD2) | [1](#s346FF33A0C2C5F81A3458BE83AC5EAD2) |
| | [Patents](#sD99363B863225ADBB197A25973F49B71) | [2](#sD99363B863225ADBB197A25973F49B71) |
| | [Trademarks](#sC8538BB25E8C5BD59956B27AFEC797A3) | [3](#sDA5547D5B40D567D8F84B76055547BCA) |
| | [Seasonality](#sDA5547D5B40D567D8F84B76055547BCA) | [3](#sDA5547D5B40D567D8F84B76055547BCA) |
| | [Competition](#s3A7E5E8E20425BD9A4432CD674D286B7) | [3](#s3A7E5E8E20425BD9A4432CD674D286B7) |
| | [Environment](#s921781027B2A5B128D05B2F0310C0EAA) | [3](#s921781027B2A5B128D05B2F0310C0EAA) |
| | [Regulation](#s8FCAB9CE9FA2586EA2AF3F41456E7EDB) | [3](#s8FCAB9CE9FA2586EA2AF3F41456E7EDB) |
| 2 | [Properties](#s3B73D9327C695F4FB85559C4690FCE42) | [11](#s3B73D9327C695F4FB85559C4690FCE42) |
| [PART II](#s5F4A58A908165FABB49BFC9E1E8B663E) | | |
| 6 | [Selected Financial Data](#sD0479B88C55257D3B269BF9479F3CD4C) | [16](#sD0479B88C55257D3B269BF9479F3CD4C) |
| 9B. | [Other Information](#s6D1FCC5E37615CC5BB902F438EBD941C) | [109](#s6D1FCC5E37615CC5BB902F438EBD941C) |
| 11 | [Executive Compensation](#sEBCED6575EB85E828D70AD4B014EED2A) | [110](#sEBCED6575EB85E828D70AD4B014EED2A) |
| [PART IV](#sF2513F90F29A524FBEC9F2A7E9EF0630) | | |
| 16 | [Form 10-K Summary](#sBEF2CE8F11565893AED5BE0C807E0650) | [111](#sBEF2CE8F11565893AED5BE0C807E0650) |
| | [Signatures](#s9877593841F3534ABAE9DBED3F121CF2) | [112](#s9877593841F3534ABAE9DBED3F121CF2) |
| | [Exhibit Index](#s4FEA1A423EEB5ADF957EC80029AD3FA9) | [114](#s4FEA1A423EEB5ADF957EC80029AD3FA9) |
An excerpt. Shown here: 40 of 76 rewritten, all 24 added and all 18 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2020 filing and the FY2019 filing.
Item 1B. UNRESOLVED STAFF COMMENTS
0 rewritten, 1 added, 0 removed, 1 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| | | | | | | 13 | | |
Item 2. PROPERTIES
14 rewritten, 5 added, 5 removed, 11 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
The Company's subsidiaries operate [removed: 97] [added: 90] manufacturing facilities occupying approximately 15.2 million square feet of floor space.
| Segment | | [added: | | | |] Square [removed: Feet (in] [added: Feet (in] thousands) | | [added: |]
| Medical Devices | | [removed: 4,825] | | [added: | | 4,951 | | |]
| Worldwide Total | | [removed: 15,153] | | [added: | | 15,194 | | |]
Within the U.S., five facilities are used by the Consumer [added: Health] segment, five by the Pharmaceutical segment and [removed: 22] [added: 19] by the Medical Devices segment.
Outside of the U.S., [removed: 25] [added: 24] facilities are used by the Consumer [added: Health] segment, 14 by the Pharmaceutical segment and [removed: 26] [added: 23] by the Medical Devices segment.
| Geographic Area | | [added: | | | |] Number of Facilities | | | [added: | | |] Square [removed: Feet (in] [added: Feet (in] thousands) | | [added: |]
| United States | | [removed: 32] | | | [removed: 4,480] | [added: 29] | [added: | | | | | 4,351 | | |]
| Western Hemisphere, excluding U.S. | | [removed: 11] | | | [removed: 1,833] | [added: 10] | [added: | | | | | 1,777 | | |]
| Africa, Asia and Pacific | | [removed: 27] | | | [removed: 2,901] | [added: 26] | [added: | | | | | 3,074 | | |]
| Worldwide Total | | [removed: 97] | | | [removed: 15,153] | [added: 90] | [added: | | | | | 15,194 | | |]
Following FDA inspections McNEIL-PPC received notifications from the FDA that all three manufacturing facilities are in conformity with applicable laws and regulations, and commercial production [removed: has] restarted in 2015.
[removed: Thus, a] [added: A] third-party expert [removed: will continue] [added: continued] to reassess the sites at various times [removed: until at least] [added: through] 2020.
Segment information on additions to property, plant and equipment is contained in Note [removed: 18] [added: 17] “Segments of Business and Geographic Areas” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
| Consumer Health | | | | | | 4,684 | | |
| Pharmaceutical | | | | | | 5,559 | | |
| Europe | | | | | | 25 | | | | | | 5,992 | | |
McNEIL-PPC is awaiting FDA inspections of the facilities which have been delayed due to COVID-19.
| | | | | | | 14 | | |
| Consumer | | 4,832 | |
| Pharmaceutical | | 5,496 | |
| Europe | | 27 | | | 5,939 | |
For information regarding lease obligations, see Note 16 “Lease Commitments” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
| | | 11 |
Item 4. MINE SAFETY DISCLOSURES
20 rewritten, 44 added, 5 removed, 8 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| Name | | [added: | | | |] Age | | [added: | | | |] Position | [added: | |]
| Joaquin Duato | | [removed: 57] | | [added: | | 58 | | | | | |] Vice Chairman, Executive Committee(a) | [added: | |]
| Peter M. Fasolo, Ph.D. | | [removed: 57] | | [added: | | 58 | | | | | |] Member, Executive Committee; Executive Vice President, Chief Human Resources Officer(b) | [added: | |]
| Alex Gorsky | | [removed: 59] | | [added: | | 60 | | | | | |] Chairman, Board of Directors; Chairman, Executive Committee; Chief Executive Officer | [added: | |]
| Ashley McEvoy | | [removed: 49] | | [added: | | 50 | | | | | |] Member, Executive Committee; Executive Vice President, Worldwide Chairman, Medical Devices(c) | [added: | |]
| Thibaut Mongon | | [removed: 50] | | [added: | | 51 | | | | | |] Member, Executive Committee, Executive Vice President, Worldwide Chairman, [removed: Consumer(d)] [added: Consumer Health(d)] | [added: | |]
| Michael E. Sneed | | [removed: 60] | | [added: | | 61 | | | | | |] Member, Executive Committee; Executive Vice President, Global Corporate Affairs and Chief Communication Officer(e) | [added: | |]
| Paulus Stoffels, M.D. | | [removed: 57] | | [added: | | 58 | | | | | |] Vice Chairman, Executive Committee; Chief Scientific Officer(f) | [added: | |]
| Jennifer L. Taubert | | [removed: 56] | | [added: | | 57 | | | | | |] Member, Executive Committee; Executive Vice President, Worldwide Chairman, Pharmaceuticals(g) | [added: | |]
| Michael H. Ullmann | | [removed: 61] | | [added: | | 62 | | | | | |] Member, Executive Committee; Executive Vice President, General Counsel(h) | [added: | |]
| Kathryn E. Wengel | | [removed: 54] | | [added: | | 55 | | | | | |] Member, Executive Committee; Executive Vice President, Chief Global Supply Chain Officer(i) | [added: | |]
| Joseph J. Wolk | | [removed: 53] | | [added: | | 54 | | | | | |] Member, Executive Committee; Executive Vice President, Chief Financial Officer(j) | [added: | |]
[removed: | (a) | Mr. J. Duato joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in the Pharmaceutical sector.] In [removed: 2009, he was named Company Group Chairman, Pharmaceuticals, and in 2011, he was named Worldwide Chairman, Pharmaceuticals. In 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals. In] July 2018, Mr. Duato was promoted to Vice Chairman of the Executive Committee, with responsibility for the company's Pharmaceutical and Consumer [added: Health] sectors, supply chain, information technology, global services and the Health & Wellness groups. [removed: |]
[removed: | (b) | Dr.] [added: (b)Dr.] P. M. Fasolo joined the Company in 2004 as Vice President, Worldwide Human Resources for Cordis Corporation, a subsidiary of the Company, and was subsequently named Vice President, Global Talent Management for the Company. [removed: He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer. Dr. Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. |]
[removed: | (c) | Ms.] [added: (c)Ms.] A. McEvoy joined the Company in 1996 as Assistant Brand Manager of McNeil Consumer Health, a subsidiary of the Company, advancing through positions of increasing responsibilities until she was appointed Company Group Chairman, Vision Care in 2012, followed by Company Group Chairman, Consumer Medical Devices in 2014. [removed: In July 2018, Ms. McEvoy was promoted to Executive Vice President, Worldwide Chairman, Medical Devices, and became a member of the Executive Committee. Ms. McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster and Johnson & Johnson Vision. |]
[removed: | (d) | Mr.] [added: (d)Mr.] T. Mongon joined the Company in 2000 as Director of Marketing for the Vision Care group in France and subsequently held general management positions as Country Manager France, Belgium and North Africa, Managing Director Latin America, and President Asia-Pacific. [removed: Mr. Mongon transitioned to the Pharmaceutical sector in 2012 as the Global Commercial Strategy Leader for the Neuroscience therapeutic area, before joining the consumer sector as Company Group Chairman Asia-Pacific. In 2019, he was promoted to Executive Vice President and Worldwide Chairman, Consumer, and became a member of the Executive Committee. Mr. Mongon has responsibility for the global development of Johnson & Johnson’s health and wellness products and solutions in beauty, OTC, oral care, baby care, women’s health, and wound care. |]
[removed: | (e) |] Mr. [removed: M. E.] Sneed [removed: joined the Company in 1983 as Marketing Assistant for Personal Products Company, a subsidiary of the Company, and gained increased responsibilities in executive positions across the global enterprise. In 2004, Mr. Sneed] was appointed [removed: Company Group Chairman, Consumer North America, followed by Company Group Chairman, Vision Care Franchise in 2007. In 2012, he became the Vice President, Global Corporate Affairs and Chief Communications Officer. Mr. Sneed was appointed] Executive Vice President, Global Corporate Affairs and Chief Communications Officer in January 2018, and became a member of the Executive Committee in July 2018, leading the Company's global marketing, communication, design and philanthropy functions. [removed: |]
[removed: | (g) | Ms. J. L. Taubert joined the Company in 2005 as Worldwide Vice President at Johnson & Johnson Pharmaceutical Services, a subsidiary of the Company.] She held several executive positions of increasing responsibility in the Pharmaceutical sector until 2012 when she was appointed Company Group Chairman, North America Pharmaceuticals, and in 2015 became Company Group Chairman, The Americas, Pharmaceuticals. [removed: In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee. Ms. Taubert has responsibility for the Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension businesses throughout Janssen. |]
[removed: | (i) | Ms. K. E. Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company.] During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. [removed: In 2010, Ms. Wengel became the first Chief Quality Officer of the Company. In 2014, she was promoted to Vice President, Johnson & Johnson Supply Chain. In July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee. |]
[removed: | (j) | Mr.] [added: (j)Mr.] J. J. Wolk joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company, and through the years held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, in Pharmaceuticals, Medical Devices and Supply Chain. [removed: From 2014 to 2016, he served as Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies of Johnson & Johnson. In 2016, Mr. Wolk became the Vice President, Investor Relations. In July 2018, he was appointed Executive Vice President, Chief Financial Officer and became a member of the Executive Committee. Mr. Wolk plays a strategic role in the overall management of the Company, and leads the development and execution of the Company's global long-term financial strategy. |]
(a)Mr. J. Duato joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in the Pharmaceutical sector.
In 2009, he was named Company Group Chairman, Pharmaceuticals, and in 2011, he was named Worldwide Chairman, Pharmaceuticals.
In 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals.
| | | | | | | 15 | | |
He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. as Chief Talent Officer.
Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee.
In April 2016, he was named Executive Vice President, Chief Human Resources Officer.
Dr. Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company.
In July 2018, Ms. McEvoy was promoted to Executive Vice President, Worldwide Chairman, Medical Devices, and became a member of the Executive Committee.
Ms. McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster and Johnson & Johnson Vision.
Mr. Mongon transitioned to the Pharmaceutical sector in 2012 as the Global Commercial Strategy Leader for the Neuroscience therapeutic area, before joining the Consumer Health sector as Company Group Chairman Asia-Pacific.
In 2019, he was promoted to Executive Vice President and Worldwide Chairman, Consumer Health, and became a member of the Executive Committee.
Mr. Mongon has responsibility for the global development of Johnson & Johnson’s health and wellness products and solutions in beauty, OTC, oral care, baby care, women’s health, and wound care.
(e)Mr. M. E. Sneed joined the Company in 1983 as Marketing Assistant for Personal Products Company, a subsidiary of the Company, and gained increased responsibilities in executive positions across the global enterprise.
In 2004, Mr. Sneed was appointed Company Group Chairman, Consumer North America, followed by Company Group Chairman, Vision Care Franchise in 2007.
In 2012, he became the Vice President, Global Corporate Affairs and Chief Communications Officer.
(f)Dr. P. Stoffels rejoined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV.
In 2005, he was appointed Company Group Chairman, Global Virology.
In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals.
Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals.
In 2012, Dr. Stoffels was appointed Chief Scientific Officer, and became a member of the Executive Committee.
In 2016, Dr. Stoffels was named Executive Vice President, Chief Scientific Officer.
In 2018, Dr. Stoffels was promoted to Vice Chairman of the Executive Committee, Chief Scientific Officer.
He is responsible for the Company’s innovation agenda across the Pharmaceutical, Medical Devices and Consumer Health sectors, product safety strategy, and the Company’s global public health strategy.
(g)Ms. J. L. Taubert joined the Company in 2005 as Worldwide Vice President at Johnson & Johnson Pharmaceutical Services, a subsidiary of the Company.
In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee.
Ms. Taubert has responsibility for the Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension businesses throughout Janssen.
(h)Mr. M. H. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department.
He was appointed Corporate Secretary in 1999 and served in that role until 2006.
During that time, he also held various management positions in the Law Department.
In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012.
In April 2016, Mr. Ullmann was named Executive Vice President, General Counsel.
Mr. Ullmann has worldwide responsibility for legal, government affairs & policy, global security, aviation, health care compliance, global brand protection and privacy.
(i)Ms. K. E. Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company.
In 2010, Ms. Wengel became the first Chief Quality Officer of the Company.
In 2014, she was promoted to Vice President, Johnson & Johnson Supply Chain.
In
| | | | | | | 16 | | |
July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee.
From 2014 to 2016, he served as Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies of Johnson & Johnson.
| | | 12 |
| (f) | Dr. P. Stoffels rejoined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals. In 2012, Dr. Stoffels was appointed Chief Scientific Officer, and became a member of the Executive Committee. In 2016, Dr. Stoffels was named Executive Vice President, Chief Scientific Officer. In 2018, Dr. Stoffels was promoted to Vice Chairman of the Executive Committee, Chief Scientific Officer. He is responsible for the Company’s innovation agenda across the Pharmaceutical, Medical Devices and Consumer sectors, product safety strategy, and the Company’s global public health strategy. |
| (h) | Mr. M. H. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department. He was appointed Corporate Secretary in 1999 and served in that role until 2006. During that time, he also held various management positions in the Law Department. In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012. In April 2016, Mr. Ullmann was named Executive Vice President, General Counsel. Mr. Ullmann has worldwide responsibility for legal, government affairs & policy, global security, aviation and health care compliance & privacy. |
| | | 13 |
| | | 14 |
An excerpt. Shown here: all 20 rewritten, 40 of 44 added and all 5 removed. The counts are complete. For every sentence, read Item 4. MINE SAFETY DISCLOSURES in the FY2020 filing and the FY2019 filing.
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
5 rewritten, 4 added, 9 removed, 3 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
As of February [removed: 12, 2020,] [added: 16, 2021,] there were [removed: 135,953] [added: 132,376] record holders of common stock of the Company.
Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note [removed: 17] [added: 16] “Common Stock, Stock Option Plans and Stock Compensation Agreements” of the Notes to Consolidated Financial Statements included in Item 8; and Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters – Equity Compensation Plan [removed: Information”.][added: Information.”]
The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of [removed: 2019.][added: 2020.]
| Fiscal Period | | [added: | | | |] Total Number of Shares Purchased(1) | | | [added: | | |] Avg. [removed: Price Paid] [added: Price Paid] Per Share | | | | [added: | |] Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or [removed: Programs(2)] [added: Programs] | | [added: | | | |] Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | [added: | |]
[removed: |] (1) [removed: |] During the fiscal fourth quarter of [removed: 2019,] [added: 2020,] the Company repurchased an aggregate of [removed: 3,061,614] [added: 2,151,333] shares of Johnson & Johnson Common Stock in open-market transactions, [added: all] of which [removed: 3,061,614 shares] were purchased in open-market transactions as part of a systematic plan to meet the needs of the Company’s compensation programs. [removed: |]
| September 28, 2020 through October 25, 2020 | | | | | | 350,000 | | | | | | $ | 145.57 | | | | | \- | | | | | | \- | | |
| October 26, 2020 through November 22, 2020 | | | | | | 369,000 | | | | | | 148.53 | | | | | | \- | | | | | | \- | | |
| November 23, 2020 through January 3, 2021 | | | | | | 1,432,333 | | | | | | 150.50 | | | | | | \- | | | | | | \- | | |
| Total | | | | | | 2,151,333 | | | | | | | | | | | | | | | | | | | | |
On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock.
Share repurchases take place from time to time on the open market or through privately negotiated transactions.
The repurchase program was completed in the fiscal third quarter of 2019.
| September 30, 2019 through October 27, 2019 | | — | | | $ | — | | | \- | | \- |
| October 28, 2019 through November 24, 2019 | | 734,409 | | | 130.60 | | | | \- | | \- |
| November 25, 2019 through December 29, 2019 | | 2,327,205 | | | 141.91 | | | | \- | | \- |
| Total | | 3,061,614 | | | | | | | | | |
| (2) | As of September 29, 2019, the share repurchase program was completed with an aggregate of 37,181,268 shares purchased for a total of $5.0 billion since the inception of the repurchase program announced on December 17, 2018. |
| | | 15 |
Item 6. Reserved
0 rewritten, 1 added, 42 removed, 0 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| | | | | | | 18 | | |
Summary of Operations and Statistical Data 2009-2019
| (Dollars in Millions Except Per Share Amounts) | 2019 | | 2018 | | 2017 | | 2016 | | 2015 | | 2014 | | | 2013 | | | 2012 | | | 2011 | | | 2010 | | | 2009 | |
| Sales to customers — U.S. | $42,097 | | 41,884 | | 39,863 | | 37,811 | | 35,687 | | 34,782 | | | 31,910 | | | 29,830 | | | 28,908 | | | 29,450 | | | 30,889 | |
| Sales to customers — International | 39,962 | | 39,697 | | 36,587 | | 34,079 | | 34,387 | | 39,549 | | | 39,402 | | | 37,394 | | | 36,122 | | | 32,137 | | | 31,008 | |
| Total sales | 82,059 | | 81,581 | | 76,450 | | 71,890 | | 70,074 | | 74,331 | | | 71,312 | | | 67,224 | | | 65,030 | | | 61,587 | | | 61,897 | |
| Cost of products sold | 27,556 | | 27,091 | | 25,439 | | 21,789 | | 21,426 | | 22,684 | | | 22,181 | | | 21,515 | | | 20,219 | | | 18,688 | | | 18,380 | |
| Selling, marketing and administrative expenses | 22,178 | | 22,540 | | 21,520 | | 20,067 | | 21,079 | | 21,887 | | | 21,650 | | | 20,697 | | | 20,800 | | | 19,296 | | | 19,712 | |
| Research and development expense | 11,355 | | 10,775 | | 10,594 | | 9,143 | | 8,999 | | 8,471 | | | 8,119 | | | 7,602 | | | 7,486 | | | 6,796 | | | 6,949 | |
| In-process research and development | 890 | | 1,126 | | 408 | | 29 | | 224 | | 178 | | | 580 | | | 1,163 | | | — | | | — | | | — | |
| Interest income | (357) | | (611) | | (385) | | (368) | | (128) | | (67 | ) | | (74 | ) | | (64 | ) | | (91 | ) | | (107 | ) | | (90 | ) |
| Interest expense, net of portion capitalized | 318 | | 1,005 | | 934 | | 726 | | 552 | | 533 | | | 482 | | | 532 | | | 571 | | | 455 | | | 451 | |
| Other (income) expense, net | 2,525 | | 1,405 | | (42) | | 210 | | (1,783) | | 82 | | | 2,903 | | | 2,004 | | | 3,115 | | | (488 | ) | | (333 | ) |
| Restructuring | 266 | | 251 | | 309 | | 491 | | 509 | | — | | | — | | | — | | | 569 | | | — | | | 1,073 | |
| | 64,731 | | 63,582 | | 58,777 | | 52,087 | | 50,878 | | 53,768 | | | 55,841 | | | 53,449 | | | 52,669 | | | 44,640 | | | 46,142 | |
| Earnings before provision for taxes on income | $17,328 | | 17,999 | | 17,673 | | 19,803 | | 19,196 | | 20,563 | | | 15,471 | | | 13,775 | | | 12,361 | | | 16,947 | | | 15,755 | |
| Provision for taxes on income | 2,209 | | 2,702 | | 16,373 | | 3,263 | | 3,787 | | 4,240 | | | 1,640 | | | 3,261 | | | 2,689 | | | 3,613 | | | 3,489 | |
| Net earnings | 15,119 | | 15,297 | | 1,300 | | 16,540 | | 15,409 | | 16,323 | | | 13,831 | | | 10,514 | | | 9,672 | | | 13,334 | | | 12,266 | |
| Add: Net loss attributable to noncontrolling interest | — | | — | | — | | — | | — | | — | | | — | | | 339 | | | — | | | — | | | — | |
| Net earnings attributable to Johnson & Johnson | 15,119 | | 15,297 | | 1,300 | | 16,540 | | 15,409 | | 16,323 | | | 13,831 | | | 10,853 | | | 9,672 | | | 13,334 | | | 12,266 | |
| Percent of sales to customers | 18.4% | | 18.8 | | 1.7 | | 23.0 | | 22.0 | | 22.0 | | | 19.4 | | | 16.1 | | | 14.9 | | | 21.7 | | | 19.8 | |
| Diluted net earnings per share of common stock (1) | $5.63 | | 5.61 | | 0.47 | | 5.93 | | 5.48 | | 5.70 | | | 4.81 | | | 3.86 | | | 3.49 | | | 4.78 | | | 4.40 | |
| Percent return on average shareholders’ equity | 25.4% | | 25.5 | | 2.0 | | 23.4 | | 21.9 | | 22.7 | | | 19.9 | | | 17.8 | | | 17.0 | | | 24.9 | | | 26.4 | |
| Percent increase (decrease) over previous year: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales to customers | 0.6% | | 6.7 | | 6.3 | | 2.6 | | (5.7) | | 4.2 | | | 6.1 | | | 3.4 | | | 5.6 | | | (0.5 | ) | | (2.9 | ) |
| Diluted net earnings per share | 0.4% | | N/M | | (92.1) | | 8.2 | | (3.9) | | 18.5 | | | 24.6 | | | 10.6 | | | (27.0 | ) | | 8.6 | | | (3.7 | ) |
| Supplementary balance sheet data: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Property, plant and equipment, net | 17,658 | | 17,035 | | 17,005 | | 15,912 | | 15,905 | | 16,126 | | | 16,710 | | | 16,097 | | | 14,739 | | | 14,553 | | | 14,759 | |
| Additions to property, plant and equipment | 3,498 | | 3,670 | | 3,279 | | 3,226 | | 3,463 | | 3,714 | | | 3,595 | | | 2,934 | | | 2,893 | | | 2,384 | | | 2,365 | |
| Total assets | 157,728 | | 152,954 | | 157,303 | | 141,208 | | 133,411 | | 130,358 | | | 131,754 | | | 121,347 | | | 113,644 | | | 102,908 | | | 94,682 | |
| Long-term debt | 26,494 | | 27,684 | | 30,675 | | 22,442 | | 12,857 | | 15,122 | | | 13,328 | | | 11,489 | | | 12,969 | | | 9,156 | | | 8,223 | |
| Operating cash flow | 23,416 | | 22,201 | | 21,056 | | 18,767 | | 19,569 | | 18,710 | | | 17,414 | | | 15,396 | | | 14,298 | | | 16,385 | | | 16,571 | |
| Common stock information | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dividends paid per share | 3.75 | | 3.54 | | 3.32 | | 3.15 | | 2.95 | | 2.76 | | | 2.59 | | | 2.40 | | | 2.25 | | | 2.11 | | | 1.93 | |
| Shareholders’ equity per share | 22.59 | | 22.44 | | 22.43 | | 26.02 | | 25.82 | | 25.06 | | | 26.25 | | | 23.33 | | | 20.95 | | | 20.66 | | | 18.37 | |
| Market price per share (year-end close) | $145.75 | | 127.27 | | 139.72 | | 115.21 | | 102.72 | | 105.06 | | | 92.35 | | | 69.48 | | | 65.58 | | | 61.85 | | | 64.41 | |
| Average shares outstanding (millions) | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| — basic | 2,645.1 | | 2,681.5 | | 2,692.0 | | 2,737.3 | | 2,771.8 | | 2,815.2 | | | 2,809.2 | | | 2,753.3 | | | 2,736.0 | | | 2,751.4 | | | 2,759.5 | |
| — diluted | 2,684.3 | | 2,728.7 | | 2,745.3 | | 2,788.9 | | 2,812.9 | | 2,863.9 | | | 2,877.0 | | | 2,812.6 | | | 2,775.3 | | | 2,788.8 | | | 2,789.1 | |
| Employees (thousands) | 132.2 | | 135.1 | | 134.0 | | 126.4 | | 127.1 | | 126.5 | | | 128.1 | | | 127.6 | | | 117.9 | | | 114.0 | | | 115.5 | |
(1) Attributable to Johnson & Johnson
An excerpt. Shown here: all 0 rewritten, all 1 added and 40 of 42 removed. The counts are complete. For every sentence, read Item 6. Reserved in the FY2020 filing and the FY2019 filing.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
1,182 rewritten, 479 added, 590 removed, 623 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| Index to Audited Consolidated Financial Statements | | [added: | | | |]
| [removed: [35](#s57844B876FBF5FB786C296A3CDC33DCA)] [added: [39](#i26b7b3066a4848f5be790a5478bde067_106)] | [added: | |] [Consolidated Balance [removed: Sheets](#s57844B876FBF5FB786C296A3CDC33DCA)] [added: Sheets](#i26b7b3066a4848f5be790a5478bde067_106)] | [added: | |]
| [removed: [36](#s7C80F5D22FA75CB184A11F1A04035897)] [added: [40](#i26b7b3066a4848f5be790a5478bde067_112)] | [added: | |] [Consolidated Statements of [removed: Earnings](#s7C80F5D22FA75CB184A11F1A04035897)] [added: Earnings](#i26b7b3066a4848f5be790a5478bde067_112)] | [added: | |]
| [removed: [37](#s62F07A40887A515CA0349D3770FFE699)] [added: [41](#i26b7b3066a4848f5be790a5478bde067_115)] | [added: | |] [Consolidated Statements of Comprehensive [removed: Income](#s62F07A40887A515CA0349D3770FFE699)] [added: Income](#i26b7b3066a4848f5be790a5478bde067_115)] | [added: | |]
| [removed: [38](#sBA61C6974B02514088A51D14F9CE0D03)] [added: [42](#i26b7b3066a4848f5be790a5478bde067_121)] | [added: | |] [Consolidated Statements of [removed: Equity](#sBA61C6974B02514088A51D14F9CE0D03)] [added: Equity](#i26b7b3066a4848f5be790a5478bde067_121)] | [added: | |]
[removed: | [39](#sFFA7B5E78C6E5F29AC5335A687FA8258) | [Consolidated Statements of Cash Flows](#sFFA7B5E78C6E5F29AC5335A687FA8258) |][added: CONSOLIDATED STATEMENTS OF CASH FLOWS]
| [removed: [41](#sA30E3FB9FB945569ABE6E75FB36C46D2)] [added: [45](#i26b7b3066a4848f5be790a5478bde067_130)] | [added: | |] [Notes to Consolidated Financial [removed: Statements](#sA30E3FB9FB945569ABE6E75FB36C46D2)] [added: Statements](#i26b7b3066a4848f5be790a5478bde067_130)] | [added: | |]
| [removed: [103](#sEF51EDF3DE7153908FBDFBA1FB3219FE)] [added: [101](#i26b7b3066a4848f5be790a5478bde067_223)] | [added: | |] [Report of Independent Registered Public Accounting [removed: Firm](#sEF51EDF3DE7153908FBDFBA1FB3219FE)] [added: Firm](#i26b7b3066a4848f5be790a5478bde067_223)] | [added: | |]
| [removed: [107](#sB6AC3450F6535291A87D22C73FDFC0E7)] [added: [104](#i26b7b3066a4848f5be790a5478bde067_226)] | [added: | |] [Management’s Report on Internal Control Over Financial [removed: Reporting](#sB6AC3450F6535291A87D22C73FDFC0E7)] [added: Reporting](#i26b7b3066a4848f5be790a5478bde067_226)] | [added: | |]
[removed: At December 29, 2019 and December] [added: | | | | | | | December] 30, [removed: 2018][added: 2018 | | | | | | | | | | | | | | | | | | December 29, 2019 | | | | | | | | |]
| | [added: | | 2020 | | | | | |] 2019 | | | | [added: | |] 2018 | | [added: |]
| Assets | | | | | | | [added: | | | | |]
| Current assets | | | | | | | [added: | | | | |]
| Cash and cash equivalents (Notes 1 and 2) | [added: | |] $ | [removed: 17,305] [added: 13,985] | | | [removed: 18,107] | | [added: 17,305 | | |]
| Marketable securities (Notes 1 and 2) | [removed: 1,982] | | [added: 11,200] | | [removed: 1,580] | | [added: | | 1,982 | | |]
| Accounts receivable trade, less allowances for doubtful accounts [removed: $226 (2018, $248)] [added: $293 (2019, $226)] | [removed: 14,481] | | [added: 13,576] | | [removed: 14,098] | | [added: | | 14,481 | | |]
| Inventories (Notes 1 and 3) | [removed: 9,020] | | [added: 9,344] | | [removed: 8,599] | | [added: | | 9,020 | | |]
| Prepaid expenses and other receivables | [removed: 2,392] | | [added: 3,132] | | [removed: 2,699] | | [added: | | 2,392 | | |]
| Assets held for sale (Note [removed: 20)] [added: 18)] | [removed: 94] | | [added: —] | | [removed: 950] | | [added: | | 94 | | |]
| Total current assets | [removed: 45,274] | | [added: 51,237] | | [removed: 46,033] | | [added: | | 45,274 | | |]
| Property, plant and equipment, net (Notes 1 and 4) | [removed: 17,658] | | [added: 18,766] | | [removed: 17,035] | | [added: | | 17,658 | | |]
| Intangible assets, net (Notes 1 and 5) | [removed: 47,643] | | [added: 53,402] | | [removed: 47,611] | | [added: | | 47,643 | | |]
| Goodwill (Notes 1 and 5) | [removed: 33,639] | | [added: 36,393] | | [removed: 30,453] | | [added: | | 33,639 | | |]
| Deferred taxes on income (Note 8) | [removed: 7,819] | | [added: 8,534] | | [removed: 7,640] | | [added: | | 7,819 | | |]
| Other assets | [removed: 5,695] | | [added: 6,562] | | [removed: 4,182] | | [added: | | 5,695 | | |]
| Total assets | [added: | |] $ | [removed: 157,728] [added: 174,894] | | | [removed: 152,954] | | [added: 157,728 | | |]
| Liabilities and Shareholders’ Equity | | | | | | | [added: | | | | |]
| Current liabilities | | | | | | | [added: | | | | |]
| Loans and notes payable (Note 7) | [added: | |] $ | [removed: 1,202] [added: 2,631] | | | [removed: 2,796] | | [added: 1,202 | | |]
| Accounts payable | [removed: 8,544] | | [added: 9,505] | | [removed: 7,537] | | [added: | | 8,544 | | |]
| Accrued liabilities | [removed: 9,715] | | [added: 13,968] | | [removed: 7,601] | | [added: | | 9,715 | | |]
| Accrued rebates, returns and promotions | [removed: 10,883] | | [added: 11,513] | | [removed: 9,380] | | [added: | | 10,883 | | |]
| Accrued compensation and employee related obligations | [removed: 3,354] | | [added: 3,484] | | [removed: 3,098] | | [added: | | 3,354 | | |]
| Accrued taxes on income (Note 8) | [removed: 2,266] | | [added: 1,392] | | [removed: 818] | | [added: | | 2,266 | | |]
| Total current liabilities | [removed: 35,964] | | [added: 42,493] | | [removed: 31,230] | | [added: | | 35,964 | | |]
| Long-term debt (Note 7) | [removed: 26,494] | | [added: 32,635] | | [removed: 27,684] | | [added: | | 26,494 | | |]
| Deferred taxes on income (Note 8) | [removed: 5,958] | | [added: 7,214] | | [removed: 7,506] | | [added: | | 5,958 | | |]
| Employee related obligations (Notes 9 and 10) | [removed: 10,663] | | [added: 10,771] | | [removed: 9,951] | | [added: | | 10,663 | | |]
| Long-term taxes payable (Note [removed: 8)] [added: 1)] | [removed: 7,444] | | [added: 6,559] | | [removed: 8,242] | | [added: | | 7,444 | | |]
| Other liabilities | [removed: 11,734] | | [added: 11,944] | | [removed: 8,589] | | [added: | | 11,734 | | |]
| | | | | | | 38 | | |
At January 3, 2021 and December 29, 2019
| | | | 101,768 | | | | | | 97,888 | | |
| | | | | | | 39 | | |
| | | | | | | 40 | | |
| | | | | | | 41 | | |
| Balance, January 3, 2021 | | | $ | 63,278 | | | | | 113,890 | | | | | | (15,242) | | | | | | 3,120 | | | | | | (38,490) | | |
| | | | | | | 42 | | |
| Contingent consideration reversal | | | (1,148) | | | | | | — | | | | | | — | | |
| Other (primarily licenses and milestones) | | | (521) | | | | | | 44 | | | | | | (464) | | |
| Credit support agreements activity, net | | | (333) | | | | | | 100 | | | | | | 25 | | |
| Other | | | (294) | | | | | | 475 | | | | | | (173) | | |
| | | | | | | 43 | | |
| | | | | | | 44 | | |
The Company adopted this standard as of the beginning of the fiscal year 2020.
ASU 2018-14: Compensation - Defined Benefit Plans
The Company adopted this standard in the fiscal year ended 2020.
This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors.
See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures.
| | | | | | | 45 | | |
Not Adopted as of January 3, 2021
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019.
There were no new material accounting standards issued in fiscal 2020 that impacted the Company.
| | | | | | | 46 | | |
the asset’s fair value and its carrying value.
| | | | | | | 47 | | |
Leases
The ROU asset pertaining to operating leases was $1.0 billion and $1.0 billion in 2020 and 2019, respectively.
The lease liability was $1.1 billion and $1.0 billion in 2020 and 2019, respectively.
| | | | | | | 48 | | |
| | | | | | | 49 | | |
The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic.
The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report.
The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets.
While there was not a material impact to the Company’s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
| | | | | | | 50 | | |
| Cash | | | | | | $ | 2,863 | | | | | — | | | | | | | | | | | | 2,863 | | | | | | 2,863 | | | | | | — | | |
| Non-U.S. Sovereign Securities(1) | | | | | | 690 | | | | | | — | | | | | | | | | | | | 690 | | | | | | — | | | | | | 690 | | |
| Corporate debt securities(1) | | | | | | 2,674 | | | | | | — | | | | | | | | | | | | 2,674 | | | | | | 1,451 | | | | | | 1,223 | | |
| Subtotal | | | | | | $ | 11,143 | | | | | — | | | | | | | | | | | | 11,143 | | | | | | 9,230 | | | | | | 1,913 | | |
| | | 34 |
| | 97,888 | | | | 94,114 | |
| | | 35 |
| | | 36 |
| | | 37 |
| Balance, January 1, 2017 | $ | 70,418 | | | 110,551 | | | | (14,901 | ) | | 3,120 | | | (28,352 | ) |
| | | 38 |
| Net earnings | $ | 15,119 | | | 15,297 | | | 1,300 | |
| Other | 44 | | | | (464 | ) | | (234 | ) |
| Other | 575 | | | | (148 | ) | | (188 | ) |
| | | 39 |
| | | 40 |
ASU 2016-02: Leases
This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements.
This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases.
The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements.
ASU 2018-02: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings.
| | | 41 |
ASU 2018-16: Derivatives and Hedging (Topic ASC 815)
This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting.
The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12.
The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments.
Not Adopted as of December 29, 2019
This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years.
ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted.
This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years.
Early adoption is permitted.
The adoption of this standard will not have a material impact on the Company’s consolidated financial statements.
| | | 42 |
| | | 43 |
sales to customers.
| | | 44 |
share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development.
| | | 45 |
| | | 46 |
| Cash | | $ | 2,619 | | | 2,619 | | | | — | |
| Other Reverse repurchase agreements | | 443 | | | | 443 | | | | — | |
| Subtotal | | $ | 9,953 | | | 9,953 | | | | — | |
| Gov't Securities | | $ | 9,474 | | | 8,144 | | | | 1,330 | |
An excerpt. Shown here: 40 of 1,182 rewritten, 40 of 479 added and 40 of 590 removed. The counts are complete. For every sentence, read Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA in the FY2020 filing and the FY2019 filing.
Item 9A. CONTROLS AND PROCEDURES
1 rewritten, 3 added, 0 removed, 12 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
*Changes in Internal Control Over Financial Reporting.* During the fiscal quarter ended [removed: December 29, 2019,] [added: January 3, 2021,] there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required under Rules 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that most of its employees are working remotely due to the COVID-19 pandemic.
The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely.
The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
3 rewritten, 2 added, 2 removed, 6 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Election of Directors” [removed: and] [added: and, if applicable,] “Stock Ownership and Section 16 Compliance – Delinquent Section 16(a) Reports” in the Proxy Statement; and the material under the caption “Executive Officers of the Registrant” in Part I of this Report.
The Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers is available on the Company’s website at *www.investor.jnj.com/gov/boardconduct.cfm*, and copies are available to shareholders [removed: without charge upon written request to the Secretary at the Company’s principal executive offices.]
Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted [added: on the Company’s website at *www.investor.jnj.com/gov.cfm* within five business days (and retained on the website for at least one year).]
| | | | | | | 106 | | |
without charge upon written request to the Secretary at the Company’s principal executive offices.
| | | 109 |
on the Company’s website at *www.investor.jnj.com/gov.cfm* within five business days (and retained on the website for at least one year).
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
8 rewritten, 2 added, 1 removed, 2 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Stock Ownership and Section 16 Compliance” in the Proxy Statement; and Note [removed: 17] [added: 16] “Common Stock, Stock Option Plans and Stock Compensation Agreements” of the Notes to Consolidated Financial Statements in Item 8 of this Report.
The following table provides certain information as of [removed: December 29, 2019] [added: January 3, 2021] concerning the shares of the Company’s Common Stock that may be issued under existing equity compensation plans.
| Plan Category | [added: | |] Number of Securities [removed: to be] [added: to be] Issued Upon Exercise [removed: of Outstanding] [added: of Outstanding] Options and Rights | | | [added: | | |] Weighted [removed: Average Exercise] [added: Average Exercise] Price [removed: of Outstanding] [added: of Outstanding] Options and Rights | | | | [added: | |] Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans(2)(3) | | [added: |]
| Equity Compensation Plans [added: Not] Approved by Security [removed: Holders(1)] [added: Holders] | [removed: 130,579,915] | | [added: \-] | | [removed: $90.31] | | | [removed: 314,776,315] | [added: \-] | [added: | | | | | \- | | |]
| Equity Compensation Plans [removed: Not] Approved by Security [removed: Holders] [added: Holders(1)] | | | [added: 131,483,837] | [removed: \-] | | | | [removed: \-] | [added: $100.98] | [added: | | | | | 276,949,737 | | |]
[removed: | (1) | Included] [added: (1)Included] in this category are the following equity compensation plans which have been approved by the Company’s shareholders: 2005 Long-Term Incentive Plan and 2012 Long-Term Incentive Plan. [removed: |]
[removed: | (2) | This] [added: (2)This] column excludes shares reflected under the column “Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.” [removed: |]
[removed: | (3) | The 2005 Long-Term Incentive Plan expired April 26, 2012.] All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. [removed: |]
| Total | | | 131,483,837 | | | | | | $100.98 | | | | | | 276,949,737 | | |
(3)The 2005 Long-Term Incentive Plan expired April 26, 2012.
| Total | 130,579,915 | | | | $90.31 | | | 314,776,315 | |
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
0 rewritten, 1 added, 1 removed, 3 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| | | | | | | 107 | | |
| | | 110 |
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
5 rewritten, 0 added, 0 removed, 9 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
Consolidated Balance Sheets at end of Fiscal Years [removed: 2019] [added: 2020] and [removed: 2018][added: 2019]
Consolidated Statements of Earnings for Fiscal Years [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017][added: 2018]
Consolidated Statements of Comprehensive Income for Fiscal Years [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017][added: 2018]
Consolidated Statements of Equity for Fiscal Years [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017][added: 2018]
Consolidated Statements of Cash Flows for Fiscal Years [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017][added: 2018]
Item 16. FORM 10-K SUMMARY
83 rewritten, 8 added, 8 removed, 9 unchanged
Read the full itemFY2020 item · filed February 22, 2021FY2019 item · filed February 18, 2020
| | | [added: | | | |] 111 | [added: | |]
Date: February [removed: 18, 2020][added: 22, 2021]
| JOHNSON & JOHNSON | [added: | |]
| (Registrant) | [added: | |]
| By | [added: | |] /s/ A. Gorsky | [added: | |]
| | [added: | |] A. Gorsky, Chairman, Board of Directors, and Chief Executive Officer | [added: | |]
| Signature | | [added: | | | |] Title | | [added: | | | |] Date | [added: | |]
| /s/ A. Gorsky | | [added: | | | |] Chairman, Board of Directors | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| A. Gorsky | | [added: | | | |] Chief Executive Officer (Principal Executive Officer) | | | [added: | | | | | |]
| /s/ J. J. Wolk | | [added: | | | |] Chief Financial Officer | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| J. J. Wolk | | [added: | | | |] (Principal Financial Officer) | | | [added: | | | | | |]
| /s/ R. J. Decker Jr. | | [added: | | | |] Controller and Chief Accounting Officer | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| R. J. Decker Jr. | | [added: | | | |] (Principal Accounting Officer) | | | [added: | | | | | |]
| /s/ M. C. Beckerle | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| M. C. Beckerle | | | | | [added: | | | | | | | | | |]
| /s/ D. S. Davis | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| D. S. Davis | | | | | [added: | | | | | | | | | |]
| /s/ I. E. L. Davis | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| I. E. L. Davis | | | | | [added: | | | | | | | | | |]
| /s/ J. A. Doudna | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| J. A. Doudna | | | | | [added: | | | | | | | | | |]
| | | [added: | | | |] 112 | [added: | |]
| Signature | | [added: | | | |] Title | | [added: | | | |] Date | [added: | |]
| /s/ M. A. Hewson | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| M. A. Hewson | | | | | [added: | | | | | | | | | |]
| /s/ H. Joly | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| H. Joly | | | | | [added: | | | | | | | | | |]
| /s/ M. B. McClellan | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| M. B. McClellan | | | | | [added: | | | | | | | | | |]
| /s/ A. M. Mulcahy | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| A. M. Mulcahy | | | | | [added: | | | | | | | | | |]
| /s/ C. Prince | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| C. Prince | | | | | [added: | | | | | | | | | |]
| /s/ A. E. Washington | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| A. E. Washington | | | | | [added: | | | | | | | | | |]
| /s/ M. A. Weinberger | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| M. A. Weinberger | | | | | [added: | | | | | | | | | |]
| /s/ R. A. Williams | | [added: | | | |] Director | | [added: | | | |] February [removed: 18, 2020] [added: 22, 2021] | [added: | |]
| R. A. Williams | | | | | [added: | | | | | | | | | |]
| Reg. S-K | | | [added: | | | | | |]
| | | | | | | 108 | | |
| | | | | | | 109 | | |
| /s/ N.Y. West | | | | | | Director | | | | | | February 22, 2021 | | |
| N. Y. West | | | | | | | | | | | | | | |
| | | | | | | 110 | | |
| [3(ii)](http://www.sec.gov/Archives/edgar/data/200406/000020040620000034/ex31amendmenttocoi.htm) | | | | | | Certificate of Amendment to the Certificate of Incorporation of Johnson & Johnson effective April 30, 2020 — Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020. | | |
| [4(b)](http://www.sec.gov/Archives/edgar/data/200406/000020040620000052/aug12exhibit41.htm) | | | | | | Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 — Incorporated herein by reference to Exhibit 4.1 of the Registrant’s Form 8-K Current Report filed August 12, 2020. | | |
| [10(n)](https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm) | | | | | | Amended and Restated Excess Benefit Plan of Johnson & Johnson and Affiliated Companies (Amended and restated effective January 1, 2020, except as otherwise provided) — Filed with this document.* | | |
| /s/ W. D. Perez | | Director | | February 18, 2020 |
| W. D. Perez | | | | |
| | | 113 |
| | | 114 |
| [10(t)](http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm) | | Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 — Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.* |
| [10(u)](http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm) | | First Amendment to the Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) — Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.* |
| [10(v)](http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm) | | Second Amendment to the Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) — Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.* |
| | | 115 |
An excerpt. Shown here: 40 of 83 rewritten, all 8 added and all 8 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2020 filing and the FY2019 filing.